ELOVL1 and melanoma: Finally, given the paucity of available biopsies from patients with PDAC under anti-PD-1 treatment, we could not validate the role of ELOVL1 in human PDAC cohorts and therefore relied on a dataset of patients with melanoma, where anti-PD-1 is a first-line treatment.